Danaher (DHR) Aperçu de l'action
Danaher Corporation conçoit, fabrique et commercialise des produits et services professionnels, médicaux, de recherche et industriels aux États-Unis, en Chine et dans le monde entier. Plus de détails
| Score flocon de neige | |
|---|---|
| Évaluation | 4/6 |
| Croissance future | 1/6 |
| Performances passées | 1/6 |
| Santé financière | 5/6 |
| Dividendes | 3/6 |
Récompenses
Analyse des risques
Aucun risque n'a été détecté pour DHR à partir de nos contrôles de risques.
DHR Community Fair Values
Create NarrativeSee what 126 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Danaher Corporation Concurrents
Historique des prix et performances
| Historique des cours de bourse | |
|---|---|
| Prix actuel de l'action | US$197.93 |
| Plus haut sur 52 semaines | US$242.80 |
| Plus bas sur 52 semaines | US$160.93 |
| Bêta | 0.82 |
| Variation sur 1 mois | 7.40% |
| Variation sur 3 mois | 3.62% |
| Variation sur 1 an | -0.85% |
| Variation sur 3 ans | -15.58% |
| Variation sur 5 ans | -28.80% |
| Évolution depuis l'introduction en bourse | 22,221.64% |
Nouvelles et mises à jour récentes
Seeking Alpha • Jun 29
Danaher: Why I'm Not Paying 24x P/E For 8% EPS Growth
Summary Danaher (DHR) is a high-quality life sciences holding company, but current valuation does not justify a buy. DHR's reliance on M&A and exposure to pharma spending cycles pose risks, with organic growth slowing to just above 4% AEPS in 2025. Despite a robust business system and strong integration track record, I see growth likely in the 4-7% range, insufficient for a 24-28x P/E. I rate DHR a 'HOLD' with a $140/share target, awaiting a more attractive entry point for market-beating upside. Read the full article on Seeking Alpha
Mise à jour du récit • Jun 26
DHR: Bioprocess Recovery And Masimo Integration Will Support Premium Multiple
Danaher’s analyst price target has been reduced by about $5 to $242, as analysts factor in a slightly higher discount rate, a more conservative profit margin, and updated views on life science tools demand that balance cautious sector sentiment with selective signs of recovery. Analyst Commentary Recent research around Danaher points to a mixed setup, with some analysts focusing on recovery potential in life science tools and bioprocessing, and others highlighting valuation questions and business complexity.Recent updates
Seeking Alpha • Jun 29
Danaher: Why I'm Not Paying 24x P/E For 8% EPS Growth
Summary Danaher (DHR) is a high-quality life sciences holding company, but current valuation does not justify a buy. DHR's reliance on M&A and exposure to pharma spending cycles pose risks, with organic growth slowing to just above 4% AEPS in 2025. Despite a robust business system and strong integration track record, I see growth likely in the 4-7% range, insufficient for a 24-28x P/E. I rate DHR a 'HOLD' with a $140/share target, awaiting a more attractive entry point for market-beating upside. Read the full article on Seeking AlphaMise à jour du récit • Jun 26
DHR: Bioprocess Recovery And Masimo Integration Will Support Premium Multiple
Danaher’s analyst price target has been reduced by about $5 to $242, as analysts factor in a slightly higher discount rate, a more conservative profit margin, and updated views on life science tools demand that balance cautious sector sentiment with selective signs of recovery. Analyst Commentary Recent research around Danaher points to a mixed setup, with some analysts focusing on recovery potential in life science tools and bioprocessing, and others highlighting valuation questions and business complexity.Mise à jour du récit • May 19
DHR: Bioprocess Recovery And Masimo Deal Set To Support Premium Multiple
Analysts have trimmed the implied fair value for Danaher by about $2 to roughly $248 per share, as they balance slightly higher long term growth and margin expectations with a lower assumed P/E multiple, evolving views on bioprocess recovery, and recent price target changes across the Street. Analyst Commentary Recent Street commentary around Danaher reflects a mixed but engaged view, with several firms adjusting price targets and reassessing how quickly the company can execute on its bioprocess ambitions and broader portfolio moves.Mise à jour du récit • May 02
DHR: Masimo Cash Acquisition Will Support Premium Future Earnings Multiple
Danaher’s updated analyst price target moves lower by about $8 per share to roughly $250, as analysts factor in more conservative assumptions for growth, profitability and future P/E multiples following a recent series of mostly downward target revisions across the Street. Analyst Commentary Recent research on Danaher reflects a mixed but generally cautious tone, with several price target cuts offset by one modest increase and a change in rating context at another company linked to Danaher’s pending acquisition activity.Mise à jour du récit • Apr 16
DHR: Masimo Cash Deal Will Support Premium Future Earnings Multiple
Danaher’s analyst price target has been reset from about $264.91 to $257.73, as analysts factor in updated assumptions around profit margins, revenue growth, discount rates and future P/E, alongside mixed recent research that includes both target raises and cuts, as well as the planned Masimo acquisition. Analyst Commentary Recent research on Danaher reflects a split view, with some firms raising their price targets and others trimming them, while the planned Masimo acquisition sits at the center of many discussions about valuation and execution risk.Mise à jour du récit • Apr 01
DHR: Cash Deal For Masimo Will Support Premium Future Earnings Multiple
Analysts have nudged Danaher’s price targets higher by low double digit dollar amounts, pointing to updated views on discount rates, revenue growth, profit margins and future P/E assumptions as the key drivers behind the revised dollar values. Analyst Commentary Recent research has focused on how Danaher’s valuation reflects expectations for future execution, especially in light of the planned Masimo acquisition and refreshed targets across the life science tools peer group.Mise à jour du récit • Mar 18
DHR: Cash Acquisition Will Support Re Rating And Premium Earnings Multiple
Analysts have nudged their price targets on Danaher higher by a few dollars into the mid $260s, citing a series of upward target revisions across the Street and support from the announced Masimo acquisition at $180 per share in cash. Analyst Commentary Recent research around Danaher has centered on the Masimo acquisition agreement at $180 per share in cash and a cluster of higher price targets that place the stock in the mid $260s to around $270.Mise à jour du récit • Mar 04
DHR: Masimo Cash Deal Will Support Re Rating And Premium Multiple
The analyst price target for Danaher has moved higher by a mid single digit dollar amount, reflecting updated assumptions for slightly stronger revenue growth and margins, alongside recent Street research that raised targets following the Masimo acquisition announcement and sector wide target adjustments. Analyst Commentary Recent Street research around Danaher reflects a mix of optimism on the Masimo acquisition and valuation, alongside a more cautious stance on deal terms and execution risk.Mise à jour du récit • Feb 17
DHR: Masimo Deal And Higher Future P/E Will Support Premium Multiple
Danaher’s updated analyst price target edges slightly lower to about $265, as analysts balance modest tweaks to revenue growth, profit margin and P/E assumptions with a broadly supportive run of recent target increases across the Street. Analyst Commentary Recent Street research on Danaher is clustered around higher price targets, with several bullish analysts lifting their numbers by single digit to low double digit dollar amounts.Mise à jour du récit • Feb 03
DHR: Higher Future P/E Assumptions Will Support Premium Multiple Through Soft 2026 Outlook
Analysts have nudged their average price target for Danaher higher, with our fair value estimate moving from US$261.50 to about US$265.23. This change is supported by a modestly higher assumed future P/E multiple and by Street research that has generally lifted targets in the life science tools sector.Mise à jour du récit • Jan 19
DHR: Share Repurchases And Soft 2026 Outlook Will Support Premium Multiple
Analysts have nudged their price targets on Danaher higher, reflected in a fair value update from US$259.23 to US$261.50, citing refreshed views on revenue growth, profit margins, and future P/E expectations in recent research. Analyst Commentary Recent price target moves on Danaher point to refreshed views on how the company could execute on growth plans, manage profitability, and justify its current P/E profile.Mise à jour du récit • Jan 05
DHR: Share Repurchases And Diagnostics Resilience Will Support Premium Multiple
Analysts have made a modest upward adjustment to their fair value estimate for Danaher to about US$259 from about US$258, reflecting slightly higher assumed profit margins and P/E, even as they highlight tempered expectations for 2025 and 2026 growth, ongoing uncertainty in China, and questions around how durable diagnostics demand will be. Analyst Commentary Analysts are split on Danaher, with some focusing on the valuation premium and others on the company’s ability to eventually reconnect with its historical growth profile.Mise à jour du récit • Dec 19
DHR: Share Repurchases Will Support Premium Multiple As Life Sciences Demand Recovers
Analysts modestly raised their blended fair value estimate for Danaher to about $258 from roughly $256, reflecting slightly lower discount rate and higher future multiple assumptions, even as they trim official price targets toward $220 amid ongoing uncertainty around the pace of life sciences and diagnostics recovery. Analyst Commentary Analysts broadly agree that Danaher's premium valuation assumes a reacceleration of growth across life sciences and diagnostics, but they remain divided on how quickly fundamentals will normalize versus the lingering headwinds in key end markets.Mise à jour du récit • Dec 04
DHR: Share Repurchases Will Support Premium Multiple Despite Slower Recovery Uncertainty
Danaher's fair value estimate has been nudged slightly higher to approximately $255.67 from about $254.20, as analysts balance still premium valuations and tempered growth expectations with signs of stabilization in key Life Sciences and Diagnostics markets. Analyst Commentary Recent Street research reflects a more balanced, wait and see stance on Danaher as investors weigh premium valuation levels against a slower growth trajectory and a gradual recovery in key end markets.Mise à jour du récit • Nov 20
DHR: Share Repurchases And Improving Profit Margins Will Drive Renewed Upside
Danaher's fair value estimate has edged slightly lower to $254.20 from $254.40, as analysts cite ongoing uncertainty in growth outlooks and mixed sector momentum. Analyst Commentary Recent analyst reports on Danaher reveal a mix of optimism around the company’s long-term positioning and concerns about near-term growth visibility and sector headwinds.Mise à jour du récit • Nov 04
DHR: Premium Outlook Will Be Sustained As Market Recovery Gradually Unfolds
Danaher’s fair value estimate has increased to $254.40 from $247.30. This reflects analysts’ view that while growth forecasts are now more gradual and discount rates slightly higher, the stock’s premium valuation still prices in a slow recovery and ongoing sector uncertainties.Mise à jour du récit • Oct 21
Analyst Commentary Highlights Mixed Sentiment and Minor Valuation Adjustments for Danaher
Analysts have marginally raised their fair value estimate for Danaher to $247.30 from $244.50, citing improved profit margins and earnings quality. However, near-term growth expectations remain tempered by ongoing market uncertainties.Mise à jour du récit • Sep 11
Advanced Diagnostics And Personalized Therapies Will Expand Global Markets
Danaher’s consensus price target saw a marginal downward revision to $244.50 as analysts incorporate more conservative near-term estimates amid continued sector weakness and tempered recovery expectations, despite steady long-term fundamentals. Analyst Commentary Bearish analysts are lowering price targets due to "more realistic" multiples and sector-wide weakness in Life Sciences Tools and Diagnostics, with a cautious view on near-term healthcare stock performance.Article d’analyse • Aug 01
Some May Be Optimistic About Danaher's (NYSE:DHR) Earnings
Danaher Corporation's ( NYSE:DHR ) recent soft profit numbers didn't appear to worry shareholders, as the stock price...Article d’analyse • Jul 12
Is Danaher Corporation (NYSE:DHR) Trading At A 33% Discount?
Key Insights Danaher's estimated fair value is US$304 based on 2 Stage Free Cash Flow to Equity Current share price of...Seeking Alpha • Mar 31
Danaher: Some Near-Term Headwinds, But Good Long-Term Prospects And Low Valuations
Summary Danaher is well-positioned for revenue growth, driven by strong Biotechnology orders, Chinese stimulus in Life Sciences, and innovative products in Diagnostics despite near-term headwinds. Margins face short-term pressure from China's VBP initiative, but cost-cutting measures and operational efficiency should drive long-term margin expansion. The stock is undervalued compared to historical levels, trading at a discount to its average forward P/E over the last five years. I maintain a buy rating on DHR stock due to its strong long-term growth prospects and attractive valuation. Read the full article on Seeking AlphaSeeking Alpha • Mar 22
Danaher: Near 5-Year Low Is A Great Entry Point
Summary Danaher Corporation is trading near its 5-year low, presenting a potential buying opportunity for growth investors despite near-term headwinds. DHR's strong fundamentals include leadership in biotechnology, life sciences, and diagnostics, with robust profitability and free cash flow. Growth catalysts include advancements in bioprocessing, molecular diagnostics, and neurodegenerative disease detection, with expected EPS growth of 10%-13% annually over the next three years. Read the full article on Seeking AlphaSeeking Alpha • Feb 17
Danaher: Self-Inflicted Pessimism?
Summary Danaher Corp. has faced market punishment recently, but maintains strong margins and impressive FCF despite a tough year, indicating resilience and potential for future growth. The company’s strategic capital allocation, including share buybacks and acquisitions, suggests management is positioning for long-term value creation, despite short-term pessimism. Danaher’s bioprocessing segment shows consistent growth, and the upcoming patent cliff is expected to provide significant tailwinds, boosting demand for their life science equipment. Valuation analysis indicates the stock is currently undervalued, with potential for significant upside as market conditions improve and growth returns, making it a buy. Read the full article on Seeking AlphaSeeking Alpha • Jan 15
Danaher Corporation: Question Mark Behind The Moat And Probably Overvalued
Summary Danaher Corporation, a key player in Life Sciences, Biotechnology, and Diagnostics, has shown mixed financial performance with recent declines in revenue and net earnings. Despite recent struggles, Danaher has strong growth potential driven by secular tailwinds like an aging population and technological advancements in diagnostics. The company exhibits a wide economic moat due to high switching costs and stable margins, but its RoIC is below the ideal threshold. Currently, Danaher is overvalued with high P/E and P/FCF ratios, making it a "Hold" rather than a buy, pending future performance improvements. Read the full article on Seeking AlphaSeeking Alpha • Jan 06
Danaher: A Wide-Moat Gem I Cannot Buy Enough Of
Summary Danaher boasts a wide-moat business model with mission-critical products and recurring revenue streams, ensuring a durable competitive advantage and long-term growth potential. The company's disciplined M&A strategy and integration capabilities have driven significant value creation, supported by strong secular healthcare trends and a focus on innovation. Despite a modest 0.5% dividend yield, Danaher's 12.4% five-year CAGR and low payout ratio offer substantial growth potential for total return investors. Trading at a reasonable valuation, Danaher is poised for a rebound with expected double-digit EPS growth, making it an excellent choice for long-term accumulation. Read the full article on Seeking AlphaRendement pour les actionnaires
| DHR | US Life Sciences | US Marché | |
|---|---|---|---|
| 7D | 2.7% | 2.1% | 1.6% |
| 1Y | -0.9% | 16.5% | 18.6% |
Rendement vs Industrie: DHR a sous-performé le secteur US Life Sciences qui a rapporté 16.5 % au cours de l'année écoulée.
Rendement vs marché: DHR a sous-performé le marché US qui a rapporté 18.6 % au cours de l'année écoulée.
Volatilité des prix
| DHR volatility | |
|---|---|
| DHR Average Weekly Movement | 4.4% |
| Life Sciences Industry Average Movement | 8.6% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.2% |
Cours de l'action stable: DHR n'a pas connu de volatilité de prix significative au cours des 3 derniers mois par rapport au marché US.
Volatilité au fil du temps: La volatilité hebdomadaire de DHR ( 4% ) est restée stable au cours de l'année écoulée.
À propos de l'entreprise
| Fondée | Salariés | PDG | Site web |
|---|---|---|---|
| 1969 | 59,000 | Rainer Blair | www.danaher.com |
Danaher Corporation conçoit, fabrique et commercialise des produits et services professionnels, médicaux, de recherche et industriels aux États-Unis, en Chine et dans le monde entier. La société exerce ses activités dans les secteurs de la biotechnologie, des sciences de la vie et du diagnostic. Le secteur de la biotechnologie fournit des technologies, des consommables, des services et des solutions qui font progresser, accélèrent et intègrent le développement et la fabrication de produits thérapeutiques ; des services de développement de lignées cellulaires et de milieux de culture cellulaire ; des milieux de culture cellulaire, des liquides de traitement et des tampons pour la fabrication, des résines de chromatographie, des technologies de filtration et des finitions de remplissage aseptique ; du matériel, des consommables et des services à usage unique, tels que la conception et l'installation de suites de fabrication complètes ; la filtration, la séparation et la purification en laboratoire ; la purification des protéines à l'échelle du laboratoire et les outils analytiques ; les réactifs, les membranes et les services pour le développement de diagnostics et d'essais ; et les solutions de filtration pour les soins de santé.
Danaher Corporation Résumé des fondamentaux
| DHR statistiques fondamentales | |
|---|---|
| Capitalisation boursière | US$140.09b |
| Bénéfices(TTM) | US$3.68b |
| Recettes(TTM) | US$24.78b |
38.1x
Ratio P/E5.7x
Ratio P/SLe site DHR est-il surévalué ?
Voir Juste valeur et analyse de l'évaluationBénéfices et recettes
| DHR compte de résultat (TTM) | |
|---|---|
| Recettes | US$24.78b |
| Coût des recettes | US$10.16b |
| Marge brute | US$14.62b |
| Autres dépenses | US$10.94b |
| Les revenus | US$3.68b |
Derniers bénéfices déclarés
Mar 27, 2026
Prochaine date de publication des résultats
Jul 21, 2026
| Résultat par action (EPS) | 5.19 |
| Marge brute | 58.99% |
| Marge bénéficiaire nette | 14.83% |
| Ratio dettes/capitaux propres | 34.9% |
Quelles ont été les performances à long terme de DHR?
Voir les performances historiques et les comparaisonsDividendes
0.8%
Rendement actuel des dividendes26%
Ratio de distributionLe site DHR verse-t-il des dividendes fiables ?
Voir DHR l'historique des dividendes et les indices de référence| Danaher dates des dividendes | |
|---|---|
| Date ex-dividende | Jun 26 2026 |
| Date de paiement du dividende | Jul 31 2026 |
| Jours jusqu'au dividende Ex | 11 days |
| Jours jusqu'à la date de paiement du dividende | 24 days |
Le site DHR verse-t-il des dividendes fiables ?
Voir DHR l'historique des dividendes et les indices de référenceAnalyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/07/06 13:24 |
| Cours de l'action en fin de journée | 2026/07/02 00:00 |
| Les revenus | 2026/03/27 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d'analyse utilisé pour générer ce rapport sont disponibles sur notre page Github, nous proposons également des guides pour apprendre à utiliser nos rapports et des tutoriels sur YouTube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Danaher Corporation est couverte par 44 analystes. 5 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| John Eade | Argus Research Company |
| Catherine Ramsey Schulte | Baird |
| Robert Cornell | Barclays |